Currently, there is no efficient targeted therapy that can prevent the metastatic dissemination of triple-negative breast cancer (TNBC). Our recent work identified PKCtheta as a potential new marker of TNBC and as a strong inducer of cancer invasion. PKCtheta is well known for its role in the immune system. However, the link between PKCtheta and cancer is extremely limited. Our project is to understand how PKCtheta controls the cancer invasion. To determine the detailed mechanism of this control, we are using cancer cells and mouse models.
Other funding : ATIP-Avenir